Navigation Links
BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
Date:10/7/2008

125 Patient, Prospective Randomized Placebo-Controlled Phase II Study Shows

Statistically Significant Improved Overall Survival.

MOUNTAIN VIEW, California, October 7 /PRNewswire/ -- BN ImmunoTherapeutics has now evaluated the mature Phase II data from the therapeutic prostate cancer vaccine candidate PROSTVAC(TM) that had been obtained as part of the recently entered partnership with the National Cancer Institute (NCI) in the US.

The results from the Phase II prospective randomized placebo-controlled study of 125 patients with advanced prostate cancer after 4 years of follow-up show that patients receiving PROSTVAC(TM) had a statistically significantly longer median overall survival by 8.5 months (p=0.015) compared to the control group. Currently the only approved treatment for advanced prostate cancer extends median overall survival by an average of approximately 2 months. In addition, PROSTVAC(TM) also had a favorable safety and tolerability profile.

Based on these promising results, BN ImmunoTherapeutics expects to initiate confirmatory Phase III studies for PROSTVAC(TM) together with the NCI in the first half of 2010 that will form the basis of approval for this therapy.

Prostate cancer is the most common form of cancer with more than 500,000 newly diagnosed patients globally per year and only limited treatment options. With estimated more than 140,000 related deaths annually, prostate cancer is the third leading cause of cancer related deaths in men.

Philip Kantoff MD, Professor of Medicine, Harvard Medical School, the principal investigator of the study, said "There are few available treatments for advanced prostate cancer. To see this extent of improvement in overall survival is very encouraging. These Phase II data with PROSTVAC(TM) warrant confirmation with a Phase III study and when confirmed this product has the potential to fulfill an unmet medical need for these patients."

Reiner Laus, President
'/>"/>

SOURCE BN ImmunoTherapeutics
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
2. Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection
3. Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
4. Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics
5. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
6. The Childrens Hospital of Philadelphia Announces New Regional Participant in The National Childrens Study
7. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
8. Resurgent Health and Medical Announces That Childrens Hospitals and Clinics of Minnesota has Ordered 25 CleanTech Automated Handwashing Systems
9. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
10. Evalve Announces Enrollment Completion of the EVEREST Randomized Study
11. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...th Africa, Nov. 26 The 2009 Frost ...ard in the Generic Pharmaceutical Market is presen...ogo: http://www.newscom.com/cgi-bin/prnh/20081117... the following criteria were used to benchmark Cip...rowth strategy and implementation, degree of innov...
(Date:11/25/2009).... 25 Pharmasset, Inc. (N...mpany committed to discovering, developing and com..., reported financial results for the fiscal year e...rmasset held $58.4 million in cash, cash equivalen...date and 2009 Highlights ,, RG7128 ,, P...
(Date:11/25/2009)...a., Nov. 25 For many of ...ally the 27 million living with untreated hearing...ys audiologist Cindy Beyer. ,, Dr. Beyer, senio...America,s largest hearing care and hearing aids ...o stress, frustration, and social isolation, "whic...
Breaking Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3Using insects to test for drug safety 56345 1Rate of teen binge drinking cut more than 1 3 by prevention system 56343 1Rate of teen binge drinking cut more than 1 3 by prevention system 56343 2Rate of teen binge drinking cut more than 1 3 by prevention system 56343 3Creation of international health links center 56339 1Creation of international health links center 56339 2
...ata To Be Presented Along With Updated Phase 1 Col...nual Meeting -, SOUTH SAN FRANCISCO, Calif. and C...harmaceuticals, Inc. (Nasdaq: PARD ), a biopharma...ced positive preliminary results,from its ongoing ...,metastatic colorectal cancer (CRC) and updated re...
...nstrates Activity in Combination with Other Target...e of Breast Cancer Settings, - First Phase II dat...GF, pathways with two oral, small molecule tyrosin...strates activity in first-line HER2 (ErbB2) positi...Phase II results combining TYKERB and AVASTIN(R) (...
Other Medicine Technology:Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 3Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 4Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 5New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 2New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 3New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 4New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 5New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 6New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 7New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 8New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 9New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 10
(Date:11/27/2009)...al, economic burdens, study predicts , ,... people with diabetes in the United States is expe... predicts. , That would bring the total by 2034... from 23.7 million today. , , At the same time, ...ple, the study also warns, rising from an estimate...
(Date:11/27/2009)...lingual coloring books designed for children ages ...y to educate - inform parents and children alike o...suars to ABC,S and a host of other topics. , ...er 27, 2009 -- Today’s children have enough ... hour of the day, but one of the oldest and simple...
(Date:11/26/2009)... -- With cold and flu season upon us, it,s more im...rol the spread of infections and avoid illness. ,...elves healthy, but to avoid transmitting illness i...ertified in infection-control), nursing director f...spital for Special Surgery (HSS) in Manhattan. ,...
(Date:11/26/2009)...lybdate (TM) has been shown in studies to be effec... caused by an overload of copper, and certain meta...owever, is known about how the drug works at the m...n University researchers now has provided an inval...bound to copper-loaded metallochaperones. The drug...
(Date:11/26/2009)...from the North Pole, Textsanta.net lets parents si... North Pole, AK (PRWEB) --... at the North Pole Santa Claus has added SMS text ... informed of his Christmas progress at the North P...t have identified a large and growing percentage o...
Breaking Medicine News(10 mins):Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
... obesity may increase a person’s risk of developin...the opposite effect.// In a recent study conduc...s for more than 20 years. They found those who wer...e age were six-times more likely to develop dement...
...as taken its toll on active baby boomers. Arthriti...e the norm //for many of the 78 million middle-age...ctive years ahead. Michael Baroli is finally ...od," he says. "If they don't work, I don't work." ...
...ost common cancer diagnosed among men in the Unite...r. There are several // treatment options, but new...disease altogether. Doctors hope that the dru...stopping testosterone’s conversion to DHT -- a mor...
... have found a way to diagnose melancholic depressi... observe // levels of certain substances in the b...epression marked by insomnia, loss of appetite, an...amate in the brain appear to be linked to melancho...
... might have a partial explanation for the loss of ...c bypass surgery.// In the gastric bypass procedur... the small proximal portion of the stomach, which ...ts who have the surgery show significant early dec...
...tamins too early may result in asthma or food alle...ing the first six months after birth has shown an ... food allergies in children who are only formula f...being male, having a smoker in the house, child ca...
Other Medicine News:
...hieve high-speed productivity in the lab with the ...for pre- and post-analytical sorting requirements....selectively decaps and then sorts primary sample t...ime, labor, and eliminate sample-handling errors. ...
Infant ThermoWrap™
COCOON Disposable Paediatric - Tube
Bair Hugger® Model 537 - Small Lower Body Blanket
Medicine Products: